These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8239587)

  • 1. Anti-Mycobacterium avium activity of quinolones: in vitro activities.
    Klopman G; Wang S; Jacobs MR; Bajaksouzian S; Edmonds K; Ellner JJ
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1799-806. PubMed ID: 8239587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.
    Klopman G; Fercu D; Renau TE; Jacobs MR
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2637-43. PubMed ID: 8913479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of new quinolones against intracellular Mycobacterium avium in human monocytes.
    Venkataprasad N; Jacobs MR; Johnson JL; Klopman G; Ellner JJ
    J Antimicrob Chemother; 1997 Dec; 40(6):841-5. PubMed ID: 9462436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Feb; 38(2):369-70. PubMed ID: 8192468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
    Barry AL; Fuchs PC
    Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of quinolones and macrolides against mycobacteria.
    Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
    J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
    Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antimicrobial activity of new quinolones against Mycobacterium avium and Mycobacterium intracellulare determined by the dilution methods using 7H11 agar and Ogawa egg media].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1993 May; 68(5):367-70. PubMed ID: 8331881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of lomefloxacin as compared with ciprofloxacin.
    Inderlied CB; Lancero MG; Bermudez LM; Young LS
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):17S-20S. PubMed ID: 2791493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.
    Waites KB; Duffy LB; Schmid T; Crabb D; Pate MS; Cassell GH
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1181-5. PubMed ID: 1929260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin.
    Yajko DM; Sanders CA; Nassos PS; Hadley WK
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2442-4. PubMed ID: 2088204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
    Barrett MS; Jones RN; Erwin ME; Koontz FP
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):169-71. PubMed ID: 1315233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; Trujillano I; García Sánchez E; García García MI; Fresnadillo MJ
    Antimicrob Agents Chemother; 1995 May; 39(5):1194-5. PubMed ID: 7625815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
    Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
    Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosis.
    Heifets LB; Lindholm-Levy PJ
    Antimicrob Agents Chemother; 1990 May; 34(5):770-4. PubMed ID: 2113793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the activity of fluoroquinolones against Mycobacterium avium in cell-free systems and a human monocyte in-vitro infection model.
    Shiratsuchi H; Jacobs MR; Pearson AJ; Venkataprasad N; Klopman G; Ellner JJ
    J Antimicrob Chemother; 1996 Mar; 37(3):491-500. PubMed ID: 9182106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.
    Perronne C; Gikas A; Truffot-Pernot C; Grosset J; Vilde JL; Pocidalo JJ
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1356-9. PubMed ID: 1656860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.